Literature DB >> 1405718

Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia.

R Pieters1, D R Huismans, A H Loonen, G J Peters, K Hählen, A van der Does-van den Berg, E R van Wering, A J Veerman.   

Abstract

Ecto-5'-nucleotidase (ecto-5'NT) catalyzes the extracellular dephosphorylation of nucleotides like IMP. Cytoplasmic 5'NT (cyto-5'NT) and non-specific (e.g. acid- and alkaline) phosphatases (AP) regulate the intracellular degradation of nucleotides. High NT and AP activities might cause a resistance to the thiopurines 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG). We studied the relation between these enzymes and immunophenotype, drug resistance and prognosis in 77 children with acute lymphoblastic leukemia (ALL). Enzyme activities were assessed radiochemically; in vitro drug resistance was measured with the MTT assay. AP activities were higher in T-ALL and B-ALL than in precursor B-ALL. Cyto-5'NT activity was very low in all phenotypes and accounted for a significant proportion of total IMPase activity only in the very immature CD10- c mu- precursor B-ALL. CD10+ ALL cases with high ecto-5'NT activities showed a trend (p = 0.065) for a lower probability of continuous complete remission than those with a low activity. Ecto-5'NT activity was not related to in vitro drug resistance to 6-TG. A weak correlation was found between in vitro 6-TG resistance and cyto-5'NT and AP activities. We conclude that high ecto-5'NT activities do not cause a resistance to 6-thiopurines in childhood ALL. Some patients have high cyto-5'NT and AP activities associated with 6-thiopurine resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405718     DOI: 10.1016/0145-2126(92)90033-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 2.  Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.

Authors:  Chelsea L Dieck; Adolfo Ferrando
Journal:  Blood       Date:  2019-03-25       Impact factor: 22.113

3.  Resistance revealed in acute lymphoblastic leukemia.

Authors:  Jon C Aster; Daniel J DeAngelo
Journal:  Nat Med       Date:  2013-03       Impact factor: 53.440

4.  NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer.

Authors:  Sifeng Hu; Fanmei Meng; Xiankun Yin; Changling Cao; Guangyong Zhang
Journal:  Biosci Rep       Date:  2019-05-17       Impact factor: 3.840

5.  Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

Authors:  Gannie Tzoneva; Arianne Perez-Garcia; Zachary Carpenter; Hossein Khiabanian; Valeria Tosello; Maddalena Allegretta; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Maddalena Paganin; Giuseppe Basso; Jana Hof; Renate Kirschner-Schwabe; Teresa Palomero; Raul Rabadan; Adolfo Ferrando
Journal:  Nat Med       Date:  2013-02-03       Impact factor: 53.440

6.  Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.

Authors:  Julia A Meyer; Jinhua Wang; Laura E Hogan; Jun J Yang; Smita Dandekar; Jay P Patel; Zuojian Tang; Paul Zumbo; Sheng Li; Jiri Zavadil; Ross L Levine; Timothy Cardozo; Stephen P Hunger; Elizabeth A Raetz; William E Evans; Debra J Morrison; Christopher E Mason; William L Carroll
Journal:  Nat Genet       Date:  2013-02-03       Impact factor: 38.330

7.  Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations

Authors:  Željko Antić; Jiangyan Yu; Simon V Van Reijmersdal; Anke Van Dijk; Linde Dekker; Wouter H Segerink; Edwin Sonneveld; Marta Fiocco; Rob Pieters; Peter M Hoogerbrugge; Frank N Van Leeuwen; Ad Geurts Van Kessel; Esme Waanders; Roland P Kuiper
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.